The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of angiotensin system inhibitors (ASIs) in the outcome of sunitinib treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC).
J. J. Kim
No relevant relationships to disclose
P. Huang
No relevant relationships to disclose
M. A. Eisenberger
No relevant relationships to disclose
R. Pili
No relevant relationships to disclose
E. S. Antonarakis
No relevant relationships to disclose
H. J. Hammers
No relevant relationships to disclose
M. A. Carducci
No relevant relationships to disclose
D. Keizman
No relevant relationships to disclose